leisure time -WSS

leisure time

author：Wikipedia 2025-10-01 02:27:17 - browse：552

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.

The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday. The Calliditas board has unanimously recommended that shareholders accept the offer, the company said, adding that it “aims to realize the benefits of being part of a larger platform” by being acquired.

Calliditas has an approved drug on the U.S. market called Tarpeyo, which treats a kidney disease called IgA nephropathy. The condition has in recent years attracted interest from a number of pharma companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： WHO recommends second malaria vaccine

hotspot

WSS

Lawsuit highlights wrinkle for disputes over surprise medical bills

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

6 solutions to address cancer drug shortages and others

Will an HIV vaccine ever be a reality?

The Karikó problem: Lessons for funding basic research

IVG is promising — but it won’t replace IVF quite yet

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

At least 13 dead in Texas as scorching temps continue

Driven by the pandemic, applicants flood public health schools

DIEP, the 'gold standard' of breast reconstruction, is under threat

Study identifies new proteins linked to dementia risk 25 years later

BioMarin wins approval for gene therapy to treat hemophilia A

Experts study whether long Covid risk adds up with each reinfection

United colonoscopy coverage change 'may cost lives,' doctors say

RSV injection headlines need to be accurate for good uptake

DIEP, the 'gold standard' of breast reconstruction, is under threat

Awakening the world to the whoosh: A patient's crusade

leisure time

Texas Department of Public Safety speaks out on migrant abuse allegations

IVG is promising — but it won’t replace IVF quite yet

The stability of $0 premiums in Medicare Advantage

Stanford president faces new allegations over 1999 paper

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

Setback for rare diseases as Taysha Gene Therapies pulls back

hotspot

hotspot

hotspot

focus